10-Q: TG Therapeutics Reports Q3 2024 Results, Achieves Net Income Amidst Continued Briumvi Growth

TG Therapeutics reports a profitable third quarter in 2024, driven by strong Briumvi sales and strategic licensing agreements, while also highlighting ongoing clinical development programs.

Summary

• TG Therapeutics reported a net income of $3.88 million for the third quarter of 2024, a significant turnaround from the $113.93 million net income in the same period last year, which was largely due to a one-time licensing payment.
• Product revenue, primarily from Briumvi sales, reached $83.3 million in Q3 2024, compared to $25.1 million in Q3 2023.
• License, milestone, royalty, and other revenue was $0.6 million in Q3 2024, a decrease from $140.7 million in Q3 2023, which included a large upfront payment from a commercialization agreement.
• The company's total revenue for Q3 2024 was $83.9 million, down from $165.8 million in Q3 2023.
• Operating income for Q3 2024 was $12.4 million, a decrease from $114.8 million in Q3 2023.
• Research and development expenses totaled $20.1 million in Q3 2024, compared to $14.8 million in Q3 2023.
• Selling, general, and administrative expenses were $42 million in Q3 2024, up from $32.8 million in Q3 2023.
• The company had $341 million in cash, cash equivalents, and investment securities as of September 30, 2024.
• TG Therapeutics believes its current financial resources, combined with projected Briumvi revenues, will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the company achieving profitability and strong Briumvi sales, but concerns remain about the decrease in overall revenue, increased expenses, and the identified material weakness in internal controls.

Positives

• The company achieved profitability in the third quarter of 2024.
• Briumvi sales continue to show strong growth.
• The company has a solid cash position to support ongoing operations.
• The initiation of a Phase 1 trial for subcutaneous ublituximab expands the potential for the drug.
• FDA clearance of the IND for azer-cel opens new avenues for development in progressive MS.

Negatives

• Total revenue decreased in Q3 2024 compared to Q3 2023 due to a significant drop in license revenue.
• Operating income decreased in Q3 2024 compared to Q3 2023.
• Research and development expenses increased in Q3 2024 compared to Q3 2023.
• Selling, general, and administrative expenses increased in Q3 2024 compared to Q3 2023.
• The company identified a material weakness in internal control over financial reporting related to non-routine share-based payment awards.

Risks

• The company faces substantial competition in the biopharmaceutical market.
• There are risks associated with commercializing drugs, including market acceptance and pricing.
• The company is subject to extensive regulation, including pricing controls and healthcare laws.
• The company relies on third parties for manufacturing and clinical trials, which introduces supply and performance risks.
• The company's intellectual property rights may be challenged or circumvented.
• The company may need to raise additional capital in the future.
• The company's stock price is volatile and subject to market fluctuations.
• The company identified a material weakness in internal control over financial reporting.

Future Outlook

The company believes its existing cash, cash equivalents, and investment securities, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will be sufficient to fund its anticipated operating cash requirements for at least twelve months following the date of this filing.

Management Comments

• The company continues to actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
• The company expects to continue to incur significant research and development expenses, as well as significant commercialization and outsourced manufacturing expenses as we continue to commercialize BRIUMVI.

Industry Context

The report reflects the ongoing trend of biopharmaceutical companies focusing on commercializing approved products while continuing to invest in research and development. The company's focus on B-cell diseases and its expansion into neurology and immunology aligns with current market trends in these therapeutic areas.

Comparison to Industry Standards

• The increase in Briumvi sales is a positive sign, but the decrease in overall revenue due to reduced licensing income highlights the volatility of such revenue streams, which is common in the biotech industry.
• The company's R&D spending is typical for a company in its stage of development, but the increase in SG&A expenses reflects the costs associated with commercializing a new product, which is consistent with industry trends.
• The company's cash position is relatively strong compared to other companies of similar size, but the need for future financing remains a possibility.
• The company's reliance on third-party manufacturers is a common practice in the industry, but it introduces supply chain risks that need to be managed effectively.
• The company's share repurchase program is a positive sign for investors, but it is not uncommon for companies to use this strategy to boost stock prices.

Related Party Transactions

• The company incurred expenses of approximately $1.1 million for the nine months ended September 30, 2024, related to shared personnel with Fortress Biotech, Inc.

Stakeholder Impact

• Shareholders may be encouraged by the company's profitability and Briumvi sales growth, but may be concerned about the decrease in overall revenue and the identified material weakness.
• Employees may be affected by the company's ongoing restructuring and cost-cutting measures.
• Customers (patients and healthcare providers) may benefit from the continued availability of Briumvi and the development of new therapies.
• Suppliers and creditors may be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• Continue commercialization efforts for Briumvi in the U.S. and Europe.
• Advance clinical development programs for subcutaneous ublituximab and azer-cel.
• Evaluate potential in-licensing, partnership, acquisition, and investment opportunities.
• Remediate the identified material weakness in internal control over financial reporting.

Key Dates

Keywords

Briumvi, ublituximab, azercabtagene zapreleucel, multiple sclerosis, RMS, biopharmaceutical, clinical trials, FDA, commercialization, revenue, net income, licensing, research and development, financial results